SOURCE: BioPharmetics, Inc.

January 23, 2006 16:00 ET

BioPharmetics, Inc., Formerly BTG Cosmetics, Signs Letter of Intent to Purchase Pharmacy

New Division to Increase Revenue by $2.5 Million

NORTH HOLLYWOOD, CA -- (MARKET WIRE) -- January 23, 2006 -- BioPharmetics, Inc. (OTC: BCSM), formerly known as BTG Cosmetics, announced the company has signed a letter of intent to purchase Boulevard Pharmacy, located in Encino, CA.

"As our business continues to expand, the purchase of Boulevard Pharmacy will not only bring in immediate revenue but will allow us to capitalize on Boulevard's 30 years of experience in compounding and pharmaceutical distribution," stated Mr. Paul Lisenby, CEO of BioPharmetics, Inc. Mr. Lisenby goes on to state, "With revenues of $2.5 million we feel this division can conservatively grow to over $5 million by 2007 and have accretive net revenues of $500,000 for 2006. This purchase also puts us in a great position to broaden our product ranges and continue to work with Biotech companies seeking solutions for manufacturing their patented formulations in the cosmetic sector."

The purchase is expected to be completed by the middle of February.

About BioPharmetics, Inc. (OTC: BCSM)

BioPharmetics, Inc., formerly known as BTG Cosmetics, Inc., is a manufacturer and distributor of quality pharmaceutical, cosmetic, and anti-aging products. The company has three divisions: biotechnology, pharmaceuticals, and cosmetics/cosmeceuticals, working in unison to develop, manufacture, and distribute, high-quality products in the retail, wholesale, and professional markets. BioPharmetics, Inc., also private labels many brands of cosmetics and Cosmeceuticals for salons and retail stores as well as compounding specialized prescriptions for doctors nationwide.

For more information, please visit their website at www.biopharmetics.net or email info@biopharmetics.net

Safe Harbor

This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.

Contact Information

  • Investor Relations
    Contact:
    Investor Relations
    Paul Deriso
    925-465-6088